Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab+vibostolimab (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYVIBE-010
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 30 Apr 2025 Planned End Date changed from 31 Mar 2031 to 27 Aug 2025.
  • 06 Apr 2025 Participants will discontinue treatment with pembrolizumab/vibostolimab, as per amendment 4. The protocol-specified futility analysis of the primary outcome measure was completed with a data cut-off of 06-Mar-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure.
  • 13 May 2024 According to Merck and Co Media Release, company announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top